Study:
A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Rationale:
n/a
Purpose:
The primary purpose of the study is to assess the potential benefit of combining two
targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will
be to determine whether the addition of Erlotinib to Avastin will improve the benefit in
metastatic renal cell carcinoma (RCC) with regard to time to progression, response rate,
duration of response, and survival compared with Avastin alone. Since Avastin has been
shown to be active in renal cancer, the goal will be to assess whether this activity can be
enhanced with Erlotinib.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Renal Cell Carcinoma
Metastases |
Drug: Avastin (bevacizumab)
Drug: Tarceva (erlotinib HCl) |
Phase 2 |
Verified by
Genentech
September, 2009
Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00081614
Study Type: Interventional
Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
The Cleveland Clinic
Cleveland, Ohio 44195
United States
n/a